Skip to main content

Table 1 Characteristics of patients at baseline

From: Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment

 

Array analysis

(n = 15)

qPCR analysis

(n = 18)

Age, years

51 (39-55)

58 (51-69)

Gender, female/male

7/8

14/4

Disease characteristics

  

   DAS28

5.6 (4.6-7.0)

5.7 (5.0-6.6)

   C-reactive protein, mg/dL

8 (6-22)

13 (5-44)

   Erythrocyte sedimentation rate

25 (12-41)

32 (16-47)

   ACPA titer, U/mL

100 (15-595)

541 (121-1,805)

   IgM RF titer, U/mL

28 (14-133)

67 (22-182)

   Disease duration, months

77 (29-240)

65 (36-1,992)

   Erosions

n = 13

n = 15

Medication

  

   Methotrexate dose, mg/week

25 (20-30)

21 (15-25)

   Prednisone

n = 2

n = 5

   NSAID

n = 7

n = 12

  1. Values are presented as median (interquartile range 25 to 75) unless indicated otherwise. ACPA, anti-citrullinated protein antibodies; DAS28, disease activity score using 28 joint counts; NSAID, nonsteroidal anti-inflammatory drug; qPCR, quantitative polymerase chain reaction; RF, rheumatoid factor.